[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n ALAEeFRWuU+fdEhSRiP1T4JOBGCgP2AeL0l995ejdPxBQZqVW1BiqC2NT6DGzlXu\n EVJ8UKV80M+i2hJn6KmMCA==\n\n', u'0000736822-04-000017.txt : 20040929\n', u'0000736822-04-000017.hdr.sgml : 20040929\n', u'20040929084701\nACCESSION NUMBER:\t\t0000736822-04-000017\nCONFORMED SUBMISSION TYPE:\t8-K\nPUBLIC DOCUMENT COUNT:\t\t2\nCONFORMED PERIOD OF REPORT:\t20040831\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nFILED AS OF DATE:\t\t20040929\nDATE AS OF CHANGE:\t\t20040929\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tIMMUCOR INC\n\t\tCENTRAL INDEX KEY:\t\t\t0000736822\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]\n\t\tIRS NUMBER:\t\t\t\t222408354\n\t\tSTATE OF INCORPORATION:\t\t\tGA\n\t\tFISCAL YEAR END:\t\t\t0531\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-14820\n\t\tFILM NUMBER:\t\t041051217\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t3130 GATWAY\n\t\tSTREET 2:\t\tPO BOX 5625\n\t\tCITY:\t\t\tNORCROSS\n\t\tSTATE:\t\t\tGA\n\t\tZIP:\t\t\t30091\n\t\tBUSINESS PHONE:\t\t7704412051\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t3130 GATEWAY DR\n\t\tSTREET 2:\t\tP O BOX 5625\n\t\tCITY:\t\t\tNORCROSS\n\t\tSTATE:\t\t\tGA\n\t\tZIP:\t\t\t30091-5625\n', u'\n', u'\n', u'8-K\n', u'1\n', u'form8k0804.htm\n', u'EARNINGS RELEASE 092904\n', u'\n', u'\n', u'UNITED STATES', u'\n                                                  SECURITIES AND EXCHANGE COMMISSION', u'\n                                                       Washington, D. C. 20549', u'\n', u'FORM 8-K', u'\n', u'CURRENT REPORT', u'\n', u'\xa0\xa0\xa0PURSUANT TO SECTION 13 OR 15(D) OF THE', u'\nSECURITIES EXCHANGE ACT OF 1934', u' ', u'\n', u'Date of Report (Date of earliest event reported):  September 29, 2004', u'\n', u'Commission File Number: ', u'0-14820', u'\n', u'IMMUCOR, INC.', u'\n(Exact name of registrant as specified in its charter)', u'\n\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'Georgia', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0  ', u'22-2408354', u'\n                  (State or other jurisdiction of incorporation or organization)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0                      (I.R.S. Employer Identification No.)', u'\n', u'3130 Gateway Drive', u'\xa0\xa0\xa0\xa0\xa0\xa0 ', u'P.O. Box 5625', u'\xa0\xa0\xa0\xa0\xa0\xa0 ', u'Norcross, Georgia 30091-5625', u'\n                                        (Address of principal executive offices)\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 (Zip Code)', u'\n', u"Registrant's telephone number, including area code, is ", u'(770) 441-2051', u'\n', u'Not applicable', u'\n', u'(Former name, former address and formal fiscal year,', u' if changed since last report)', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 1; page: 1" ', u'\n', u'\n', u' MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" ', u'\n', u'\n', u'Item 12. Results of\nOperations and Financial Condition ', u'\n', u' MARKER FORMAT-SHEET="Para Indent" FSL="Default" ', u'\n', u"\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Immucor,\nInc. (the \x93Company\x94) issued a press release on September 29, 2004 announcing the\nCompany\x92s  earnings and certain other results of operations for the fiscal\nfirst quarter for the year ending May 31, 2005 and discussed the Company\x92s outlook for\nfiscal year 2005. This press release is furnished with this Current Report as Exhibit\n99.1.  Edward L. Gallup, the Company's Chairman, Dr. Gioacchino De Chirico, the Company's President and Chief Executive Officer, and Steven C.\nRamsey, the Company's Vice President and Chief Financial Officer, hosted a conference call on September 29, 2004 to review the\ncontents of the press release and to answer questions from investors. ", u'\n', u' MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" ', u'\n', u'\n', u'Item 7. Financial\nStatements and Exhibits. ', u'\n', u' MARKER FORMAT-SHEET="Head Left" FSL="Default" ', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0', u'(c) Exhibits.', u' ', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0EXHIBIT NO.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0DESCRIPTION', u'\n\n\xa0\xa0\xa0\xa0\xa0\xa0\xa099.1\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Press Release dated September 29, 2004.', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 2; page: 2" ', u'\n', u'\n', u' MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" ', u'\n', u'\n', u'SIGNATURES ', u'\n', u' MARKER FORMAT-SHEET="Para Large Indent"  ', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused\nthis report to be signed on its behalf by the undersigned thereunto duly authorized. ', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0IMMUCOR, INC.', u'\n', u'Date:\xa0\xa0\xa0September 29, 2004\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0By:   ', u'/s/\xa0Steven C. Ramsey', u'\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Steven C. Ramsey', u'\n\n\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Chief Financial Officer', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 3; page: 3" ', u'\n', u'\n', u' MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" ', u'\n', u'\n', u'EXHIBIT INDEX ', u'\n', u'\xa0\xa0\xa0\xa0\xa0\xa0\xa0EXHIBIT NO.\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0DESCRIPTION', u'\n\n\xa0\xa0\xa0\xa0\xa0\xa0\xa099.1\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0Press Release dated September 29, 2004.', u'\n', u'\n', u'\n', u'\n', u'EX-99\n', u'2\n', u'form8k0804ex99_1.htm\n', u'EARNINGS RELEASE 092904\n', u'\n', u'\n', u'Exhibit 99.1', u'\n', u'FOR IMMEDIATE RELEASE ', u'\nCONTACT:\xa0  Edward Gallup ', u'\n770-441-2051\xa0 ', u'\n', u' MARKER FORMAT-SHEET="Head Major Center Bold" FSL="Default" ', u'\n', u'IMMUCOR ANNOUNCES\nRECORD FIRST QUARTER RESULTS', u'Exceeds Consensus EPS Raises 2005 guidance ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'NORCROSS, GA. (September 29, 2004)\n\x96 Immucor, Inc. (Nasdaq/NM: BLUD), the global leader in providing automated\ninstrument-reagent systems to the blood transfusion industry, today reported financial\nresults for the fiscal first quarter ended August 31, 2004 and raised its guidance for the\nfiscal year.   ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Revenue for the fiscal first quarter\nwas a record $32.1 million, up 17.8% from $27.3 million in the same period last year; $1.9\nmillion of the revenue for the quarter just ended came from price increases. Gross margin\nimproved during the quarter to 57.0% up from 55.7% in the prior year quarter and 55.9% in\nthe fiscal fourth quarter. Net income for the first quarter was $4.9 million versus a net\nincome of $3.7 million for the same quarter last year. Diluted earnings per share,\ntotaling $0.16 on 31.7 million weighted average shares outstanding, were above the\nconsensus estimates of covering analysts and compare with $0.12 on 31.0 million weighted\naverage shares outstanding for the same period last year. All share and per share amounts\nhave been adjusted to reflect the 3-for-2 stock split effected in the form of a 50% stock\ndividend which was effective for shareholders of record as of June 30, 2004.', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Sales of instruments were $2.8\nmillion in the first quarter of fiscal 2005, slightly more than the $2.5 million in the\nfiscal 2004 first quarter. Instrument sales are very unpredictable due to the long sales\ncycle. The backlog of purchase orders received and instruments installed at customers\nsites but not yet recorded as sales was $1.0 million at the end of the 2005 first quarter. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Reagent gross margin (i.e., gross\nprofit as a percent of sales) grew to 62.0% during the first quarter of fiscal 2005\ncompared to 60.8% in the same period last year. This increase was driven by increased\nsales of Capture\xae products and increased manufacturing efficiencies due in part to the\nconsolidation of the manufacture of red blood cells into the Norcross facility. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Research and development expenses\nwere $1.1 million in the first quarter, up 37.9% from $790 thousand in the prior year\nquarter. Spending on the development of the new third generation instrument targeted for\nthe small to medium hospital market was $421 thousand in the first quarter, an increase of\n$351 thousand over the same period last year.  ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'\x93Our\nstrategic plan continues to be very effective as evidenced by record revenues, expansion\nof operating margins and growth in net income,\x94 said Edward L. Gallup, Chairman.\n\x93Gross margins exceeded our internal goal for the first quarter and we expect to see\ncontinued improvement throughout the fiscal year.\x94 ', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 6; page: 6" ', u'\n', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Dr. Gioacchino De Chirico, President and CEO said, \x93We are very proud of the\n          job our management team has done in controlling costs while we experience above\n          average growth in revenues. We believe we are well positioned to continue to\n          achieve market share gain and revenue growth through continued instrument\n          placements and a well designed pricing strategy. Demand for our Galileo high\n          volume instrument continues to be robust in the European market. Today there are\n          158 Galileo placements worldwide: 147 in Europe, 6 in the United States and 5 in\n          Japan. In addition we have signed commitments for an additional 4 instruments in\n          North America.\x94 ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Commenting further, Dr. De Chirico\nstated, \x93Based on our current view of the business we are raising our revenue and\nearnings guidance for the year with most of the increase coming in our fiscal third and\nfourth quarter.\x94 ', u'\n', u' MARKER FORMAT-SHEET="Head Left" FSL="Default" ', u'\n', u'\n', u'Selected Highlights', u' ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'-Sales of traditional reagent\nproducts, i.e., products not utilizing the Company\x92s patented Capture\xae\ntechnology, increased $2.1 million, or 10.4%, from $20 million in the first quarter of\n2004 to $22.1 million in the first quarter of 2005. Sales of Capture\xae products\nincreased approximately $1.6 million to $6.4 million, a 33.7% increase over the prior year\nquarter.\xa0Human collagen sales were $789 thousand during the quarter. There were no\nsales of collagen in the corresponding prior year period.  ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'-The gross margin on traditional\nreagents was 57.4% for the current quarter, compared with 58.4% in the prior year quarter.\nThe decrease in gross margin is primarily due to ongoing regulatory costs to support CE\nmarking in Europe. The gross margin on Capture\xae products was 77.8% for the current\nquarter, compared with 70.5% in the prior year quarter. The gross margin on human collagen\nsales was 30.0% during the quarter. ', u'\n', u' MARKER FORMAT-SHEET="Para Indent" FSL="Default" ', u'\n', u'-Sales of instruments were $2.8\nmillion in the first quarter of 2005 compared to $2.5 million in the first quarter of\n2004. The gross margin on instruments, including the impact of the cost of providing\nservice was 13.9% for the current quarter, compared to 9.8% for the same quarter last\nyear. Instrument gross margin benefited from higher warranty revenue during the period due\nto a higher number of instruments under warranty, as well as increases in warranty\ncontract pricing. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'-The effect on revenues of the change\nin the Euro exchange rate was an increase of $522 thousand for the first quarter of 2005.\nThe effect on net income of the change in the Euro exchange rate for this same period was\nminor for the quarter ended August 31, 2004.', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'-Selling, marketing, distribution and\ngeneral and administrative expenses increased by $578 thousand for the first quarter of\n2005 as compared to the prior year quarter, due to additional personnel and expenditures\nto support domestic and international efforts to expand Company presence, and assure\ncompliance with European Union quality regulations and accounting and SEC regulatory\nmandates in the United States. The effect on operating expenses of the change in the Euro\nexchange rate was an increase of $212 thousand for the quarter. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'-Other income (loss) includes a $274\nthousand charge associated with the buyout of a distribution agreement. ', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 7; page: 7" ', u'\n', u'\n', u' MARKER FORMAT-SHEET="Head Major Left Bold" FSL="Default" ', u'\n', u'2005 Guidance ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'The following guidance reflects\nImmucor\x92s expectations as of September 29, 2004 and is being provided so that the\nCompany can discuss its future outlook during its upcoming conference call with investors,\npotential investors, the media, financial analysts and others. These forward-looking\nstatements are subject to the cautionary paragraph at the end of this press release and\nassume that the factors mentioned in that paragraph will not have a material impact on\nexpected results. Investors are cautioned against attributing undue certainty to\nmanagement\x92s assessment of the future and that actual results could differ. The\nCompany does not intend to update its outlook until its second quarter earnings\nannouncement, which is tentatively planned for mid-January 2005.', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'The Company expects revenues for the\nfiscal year ending May 31, 2005 to range from $133 million to $135 million, an increase of\napproximately 18% to 19% over fiscal 2004 revenues. Gross margin is expected to be in the\nrange of 56.5% to 57.5%. Net income is expected to be in the range of $23.2 million to\n$23.9 million, an approximate 86% to 91% increase over fiscal 2004. We expect to generate\nrecord earnings per diluted share in the range of $0.73 to $0.75 for the fiscal year. We\nbase our projections on our history of operations and experience, the recurring nature of\nour revenues, including contractually committed purchases from large customers, and the\npredictability of our expenses through the fiscal year. In making this projection,\nmanagement has made the following assumptions: ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'With respect to revenues, the Company\nhas extrapolated recent past results and assumed the Company will generate additional\nrevenues from the renewal of customer contracts at higher prices, the continuing sales of\nABS2000 in the United States', u',', u' the continuing sales of the Galileo instrument in\nEurope and new Galileo sales in Japan and the United States, the associated reagent growth\nassociated with these instrument placements, and sales of the human collagen product. The\nCompany has also assumed 2005 sales of human collagen to range between $3.0 million and\n$4.0 million. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'With respect to the operations of its\nforeign subsidiaries, the Company has assumed that there will be no significant change in\nforeign exchange conversion rates. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'With respect to diluted earnings per\nshare, the Company\x92s projection assumes that there will not be additional capital\nstock issued.', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Immucor, Inc. will host a conference\ncall September 29, 2004 at 11:00 a.m. (EST) to review the results. Investors are invited\nto participate in this conference call with Edward L. Gallup, Chairman, Dr. Gioacchino De\nChirico, President and Chief Executive Officer and Steven C. Ramsey, Vice President and\nChief Financial Officer. The call will focus on the results for the first quarter, general\nbusiness trends, and the Company\x92s outlook for fiscal 2005. This earnings release\nwill be posted on Immucor\x92s website, as well as any financial information that may be\ndiscussed by Messrs. Gallup, De Chirico or Ramsey during this call that is not contained\nin the earnings release. Both this earnings release and the additional financial\ninformation, if any, will be posted as soon as practicable after the call on the investor\nnews section of Immucor\x92s website. To access this information once posted, go to\nImmucor\x92s website at ', u'www.immucor.com', u' and click on \x93Investor News.\x94 ', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 1; page: 1" ', u'\n', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'To participate in the telephone\nconference call, dial 1-888-566-5774, password BLUD. Replays of the conference call will\nbe available for one week beginning at 1:00 PM on September 29 by calling\n1-866-499-4574.\xa0 Beginning October 6, 2004, audio of the conference call or a\ntranscript of the audio will be available on the \x93Investor News\x94 page of the\nImmucor website. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Founded in 1982, Immucor manufactures\nand sells a complete line of reagents and systems used by hospitals, reference\nlaboratories and donor centers to detect and identify certain properties of the cell and\nserum components of blood prior to transfusion. Immucor markets a complete family of\nautomated instrumentation for all of its market segments. ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'For more information on Immucor,\nplease visit our website at ', u'www.immucor.com.', u'. \xa0 ', u'\n', u' MARKER FORMAT-SHEET="Para Flush" FSL="Default" ', u'\n', u'Statements contained in this press\nrelease that are not statements of historical fact are \x93forward-looking\nstatements\x94 as that term is defined under federal securities laws, including, without\nlimitation, all statements concerning Immucor\x92s expectations, beliefs, intentions or\nstrategies for the future. Forward-looking statements may be identified by words such as\n\x93plans,\x94 \x93expects,\x94 \x93believes,\x94 \x93anticipates,\x94\n\x93estimates,\x94 \x93projects,\x94 \x93will,\x94 \x93should\x94 and\nother words of similar meaning used in conjunction with, among other things, discussions\nof future operations, financial performance, product development and new product launches,\nFDA and other regulatory applications and approvals, market position and expenditures.\nFactors that could cause actual results to differ materially from those expressed in any\nforward-looking statement include the following: the decision of customers to defer\ncapital spending, increased competition in the sale of instruments and reagents, product\ndevelopment or regulatory obstacles, changes in interest rates, fluctuations in foreign\ncurrency conversion rates, changes in demand for the Company\x92s human collagen\nproduct, and general economic conditions. Further risks are detailed in the Company\x92s\nfilings with the Securities and Exchange Commission. Investors are cautioned not to place\nundue reliance on any forward-looking statements. Immucor assumes no obligation to update\nany forward-looking statements.', u'\xa0 ', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 5; page: 5" ', u'\n', u'\n', u' ', u'IMMUCOR, INC.', u'\nCONDENSED CONSOLIDATED STATEMENTS OF INCOME', u'(Unaudited)', u'\n', u'\n', u'\n', u'\n', u'\n', u'Three Months Ended', u'\n', u'\n', u'\n', u'August 31,', u'\n', u'August 31,', u'\n', u'\n', u'\n', u'2004', u'\n', u'2003', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'NET SALES', u'\n', u'\xa0', u'\n', u'$\xa032,102,211', u'\n', u'\xa0', u'\n', u'$\xa027,261,648', u'\n', u'\xa0', u'\n', u'\n', u'COST OF SALES', u'\n', u'\xa0', u'\n', u'13,789,739', u'\n', u'\xa0', u'\n', u'12,073,580', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'GROSS PROFIT', u'\n', u'\xa0', u'\n', u'18,312,472', u'\n', u'\xa0', u'\n', u'15,188,068', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'OPERATING EXPENSES:', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0Research and development', u'\n', u'\xa0', u'\n', u'1,088,806', u'\n', u'\xa0', u'\n', u'789,789', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0Selling and marketing', u'\n', u'\xa0', u'\n', u'4,066,386', u'\n', u'\xa0', u'\n', u'3,665,550', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0Distribution', u'\n', u'\xa0', u'\n', u'1,939,017', u'\n', u'\xa0', u'\n', u'2,178,901', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0General and administrative', u'\n', u'\xa0', u'\n', u'3,016,932', u'\n', u'\xa0', u'\n', u'2,603,602', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0Amortization expense', u'\n', u'\xa0', u'\n', u'96,063', u'\n', u'\xa0', u'\n', u'92,094', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0Total operating expenses', u'\n', u'\xa0', u'\n', u'10,207,204', u'\n', u'\xa0', u'\n', u'9,329,936', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'INCOME FROM OPERATIONS', u'\n', u'\xa0', u'\n', u'8,105,268', u'\n', u'\xa0', u'\n', u'5,858,132', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0Interest income', u'\n', u'\xa0', u'\n', u'136,627', u'\n', u'\xa0', u'\n', u'2,815', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0Interest expense', u'\n', u'\xa0', u'\n', u'(106,332', u'\n', u')', u'\n', u'(325,372', u'\n', u')', u'\n', u'\n', u'\xa0\xa0\xa0Other income (loss)', u'\n', u'\xa0', u'\n', u'(295,204', u'\n', u')', u'\n', u'122,981', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0Total other', u'\n', u'\xa0', u'\n', u'(264,909', u'\n', u')', u'\n', u'(199,576', u'\n', u')', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'INCOME BEFORE INCOME TAXES', u'\n', u'\xa0', u'\n', u'7,840,359', u'\n', u'\xa0', u'\n', u'5,658,556', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'INCOME TAXES', u'\n', u'\xa0', u'\n', u'2,891,406', u'\n', u'\xa0', u'\n', u'1,982,715', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'NET INCOME', u'\n', u'\xa0', u'\n', u'$\xa0\xa04,948,953', u'\n', u'\xa0', u'\n', u'$\xa0\xa0\xa03,675,841', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'EARNINGS PER SHARE', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0\xa0Per common share', u'\n', u'\xa0', u'\n', u'$\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa00.16', u'\n', u'\xa0', u'\n', u'$\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa00.13', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0Per common share - assuming dilution', u'\n', u'\xa0', u'\n', u'$\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa00.16', u'\n', u'\xa0', u'\n', u'$\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa00.12', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'WEIGHTED AVERAGE SHARES OUTSTANDING: ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0\xa0\xa0Basic', u'\n', u'\xa0', u'\n', u'30,070,425', u'\n', u'\xa0', u'\n', u'29,082,157', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0\xa0\xa0\xa0Diluted', u'\n', u'\xa0', u'\n', u'31,705,901', u'\n', u'\xa0', u'\n', u'30,988,292', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u' *************************************************************************** ', u'\n', u' MARKER PAGE="sheet: 4; page: 4" ', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'IMMUCOR, INC', u'\n', u'\n', u'Selected Consolidated Balance Sheet Items', u'\n', u'\xa0', u'\n', u'\n', u'\xa0\xa0', u'\n', u'August 31, 2004', u'\n', u'\xa0\xa0', u'\n', u'May 31, 2004', u'\n', u'\n', u'\xa0', u'\n', u'(Unaudited)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash', u'\n', u'$\xa0\xa0\xa013,148,628\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'$\xa0\xa0\xa015,697,082\xa0\xa0\xa0', u'\n', u'\n', u'Accounts receivable\xa0\x96\xa0trade', u'\n', u'27,773,765\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'26,533,796\xa0\xa0\xa0', u'\n', u'\n', u'Inventory', u'\n', u'20,738,053\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'20,160,858\xa0\xa0\xa0', u'\n', u'\n', u'Total current assets', u'\n', u'66,883,388\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'68,623,081\xa0\xa0\xa0', u'\n', u'\n', u'Property and equipment-net', u'\n', u'22,576,816\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'22,846,358\xa0\xa0\xa0', u'\n', u'\n', u'Total assets', u'\n', u'122,403,192\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'124,416,827\xa0\xa0\xa0', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'Current portion-long-term debt, capital leases and lines of credit', u'\n', u'4,903,922\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'5,842,578\xa0\xa0\xa0', u'\n', u'\n', u'Accounts payable', u'\n', u'8,522,114\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'8,116,645\xa0\xa0\xa0', u'\n', u'\n', u'Total current liabilities', u'\n', u'21,678,943\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'20,362,395\xa0\xa0\xa0', u'\n', u'\n', u'Long-term debt, capital leases, lines of credit and other liabilities', u'\n', u'9,980,169\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'11,101,333\xa0\xa0\xa0', u'\n', u'\n', u"Shareholders' equity", u'\n', u'\xa090,744,080\xa0\xa0\xa0', u'\n', u'\xa0\xa0', u'\n', u'\xa092,953,099\xa0\xa0\xa0', u'\n', u'\n', u'\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']